Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370651 · ClinicalTrials.gov registry record · NA
Emsella Chair vs Sham for Male Sexual Dysfunction
A NA study of Ejaculatory Dysfunction and Male Sexual Dysfunction, sponsored by Corewell Health East.
- Recruiting
- Registry status
- NA
- Development phase
- 117
- Enrollment target
- 1
- Study location
NCT05370651: Recruiting NA study of Ejaculatory Dysfunction and Male Sexual Dysfunction, sponsored by Corewell Health East.
NCT05370651 is a NA study of Ejaculatory Dysfunction and Male Sexual Dysfunction that is actively recruiting participants, run by Corewell Health East. The registered enrollment target is 117 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05370651, a NA study of Ejaculatory Dysfunction and Male Sexual Dysfunction, is actively recruiting participants, sponsored by Corewell Health East.
- RECRUITING
- Registry status
- NA
- Development phase
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
We will be performing this study in 2 phases: Phase 1 will be an open label pilot study of 10 male participants. All participants in the pilot study will receive active treatment. If data from the pilot study is suggestive of symptom improvement, we will continue on to phase 2, which is a sham controlled, randomized blinded study. Participants in phase 2 will be randomized to receive either active treatment or sham. Potentially a total of 117 participants for both phases will be enrolled. The purpose of this study is to compare the Emsella Chair to sham and to determine whether electromagnetic technology is effective in the treatment of sexual dysfunction, specifically erectile dysfunction (EjD) in men.
Primary Outcome
The GRA is a validated single question survey prompting subjects to rank change in symptom severity since the start of therapy on a 7-point scale (1 = markedly worse, 2 = moderately worse, 3 = mildly worse, 4 = same, 5= slightly improved, 6 = moderately improved, 7= markedly improved). A score equal to or above 5 will show improvement. A score of 4 will mean no change. A score equal to or below 3 will show worsening of symptoms.
Conditions Studied
Interventions
- DEVICE BTL Emsella Chair
Study Locations (1)
Michigan
- Corewell Health William Beaumont University Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT05370651 shows while recruiting
NCT05370651 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Ejaculatory Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which BTL Emsella Chair is the first listed.
NCT05370651 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05370651 about?
NCT05370651 is a clinical study titled "Emsella Chair vs Sham for Male Sexual Dysfunction". We will be performing this study in 2 phases: Phase 1 will be an open label pilot study of 10 male participants. All participants in the pilot study will receive active treatment. If data from the pilot study is suggestive of symptom improvement, we will continue on to phase 2, which is a sham contr...
What is the current status of trial NCT05370651?
This trial is currently recruiting. It is a NA study. The enrollment target is 117 participants. The study started on 2022-12-14. Estimated completion is 2027-12.
What conditions does trial NCT05370651 study?
This clinical trial studies the following conditions: Ejaculatory Dysfunction, Male Sexual Dysfunction.
What interventions are being tested in trial NCT05370651?
The interventions under investigation include: BTL Emsella Chair (DEVICE).
Who is sponsoring clinical trial NCT05370651?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05370651 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ejaculatory Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05370651's enrollment target sits among peer trials
117 807th of 2000 higher than 1,193 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI